Lenalidomide Capsule
Product Images NDC 70710-1031

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Lenalidomide (NDC 70710-1031). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Zydus Pharmaceuticals Usa Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image (D06dec99 06d1 4525 9caf 460747b53fbc 01)

Chemical structure of lenalidomide, showing the arrangement of its molecular components as depicted in the formula image.*

FDA Label Image

Image (D06dec99 06d1 4525 9caf 460747b53fbc 02)

A survival probability Kaplan-Meier curve chart showing progression-free survival (months) for three treatment groups labeled Rd Continuous, Rd18, and MPT in patients taking lenalidomide. The y-axis represents survival probability (%) and the x-axis shows months of progression-free survival. The chart includes a table of the number of subjects at risk over time and displays hazard ratios (HR) with confidence intervals (CI) and a log-rank p-value indicating statistical comparison of the treatment groups.*

FDA Label Image

Image (D06dec99 06d1 4525 9caf 460747b53fbc 03)

A Kaplan-Meier survival curve chart showing Overall Survival (months) on the x-axis and Survival Probability (%) on the y-axis. The chart compares three treatment groups: Rd Continuous, Rd18, and MPT. It includes a table of the number of subjects at risk over time and hazard ratio statistics with confidence intervals. Additional abbreviations and explanations are provided for terms used in the chart.*

FDA Label Image

Image (D06dec99 06d1 4525 9caf 460747b53fbc 04)

A survival curve graph depicting the proportion of subjects over time to progression in months. The graph compares Lenalidomide/Dex treatment versus Placebo/Dex, showing Lenalidomide/Dex with a higher proportion of subjects without progression over time. Statistical data including hazard ratio and p-value are displayed.*

FDA Label Image

Image (D06dec99 06d1 4525 9caf 460747b53fbc 05)

A Kaplan-Meier survival curve comparing time to progression (months) on the x-axis with the proportion of subjects on the y-axis. Two curves are shown: one for Lenalidomide/Dex labeled in blue and one for Placebo/Dex labeled in red. The graph includes a hazard ratio (HR) with 95% confidence interval (0.324, 0.240-0.438) and a Log Rank p-value less than 0.001.*

FDA Label Image

Label (D06dec99 06d1 4525 9caf 460747b53fbc 06)

Lenalidomide Capsules 2.5 mg oral dosage form by Zydus Pharmaceuticals USA Inc. The label includes the NDC number 70710-1030-7 and contains 28 capsules. It features a warning about the potential for human birth defects and instructs pharmacists to dispense the Medication Guide. Storage instructions and manufacturer details (Zydus Lifesciences Ltd., India) are also provided.*

FDA Label Image

Sl-5mg-28c (D06dec99 06d1 4525 9caf 460747b53fbc 07)

Lenalidomide Capsules 5 mg oral dosage form label from Zydus Pharmaceuticals USA Inc. The label displays the NDC 70710-1031-7 and includes a warning about potential human birth defects. It states the package contains 28 capsules for prescription use only. Storage instructions, manufacturer details (Zydus Lifesciences Ltd., India), and distributor information (Zydus Pharmaceuticals USA Inc., NJ) are also visible.*

FDA Label Image

Sl-10mg-28c (D06dec99 06d1 4525 9caf 460747b53fbc 08)

Packaging label for Lenalidomide Capsules 10 mg by Zydus Pharmaceuticals USA Inc. The label states each hard gelatin capsule contains 10 mg of Lenalidomide and includes warnings about potential human birth defects. The package contains 28 capsules with Rx-only designation. Storage instructions and distributor details are also provided.*

FDA Label Image

Sl-15mg-21c (D06dec99 06d1 4525 9caf 460747b53fbc 09)

Label for Lenalidomide Capsules 15 mg by Zydus Pharmaceuticals USA Inc. The label shows the product name, strength, and contains a warning about potential human birth defects. The package includes 21 capsules for prescription use only. Storage instructions and manufacturer details are also present.*

FDA Label Image

Sl-20mg-21c (D06dec99 06d1 4525 9caf 460747b53fbc 10)

Packaging label of Lenalidomide Capsules 20 mg manufactured by Zydus Pharmaceuticals USA Inc. The label states the product contains 21 hard gelatin capsules with each containing 20 mg Lenalidomide. It includes storage instructions, a warning about potential human birth defects, and pharmacist dispensing guidance. The label shows the NDC code 70710-1034-8 and manufacturer information for Zydus Lifesciences Ltd., Ahmedabad, with distribution by Zydus Pharmaceuticals (USA) Inc., Pennington, NJ.*

FDA Label Image

Sl-25mg-21c (D06dec99 06d1 4525 9caf 460747b53fbc 11)

Lenalidomide Capsules 25 mg hard gelatin capsules by Zydus Pharmaceuticals USA Inc. The label indicates a package count of 21 capsules for oral use. It includes a warning about potential human birth defects and directs pharmacists to dispense the Medication Guide. Storage instructions are listed, and manufacturing and distribution details are provided, including Zydus Lifesciences Ltd. and Zydus Pharmaceuticals (USA) Inc.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.